title: Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016).
abstract: Endogenous Cushing's syndrome (CS) is a set of disorders caused by chronic exposure to excess glucocorticoids induced by neuroendocrine tumors in pituitary, adrenals, and infrequently other sites (ectopic ACTH syndrome). Due to various comorbidities, CS patients exhibit higher risks of cardiovascular diseases and thus increased mortality. Pharmaceutical therapy is an important constituent of treatment regimen. Areas covered: Patents published since 2012 are reviewed, which claim therapeutic compounds interfering with ACTH secretion and down-stream signal transduction, inhibiting cortisol biosynthesis and antagonizing glucocorticoid receptors. Advances focus on a) new analogues with improved efficacy and PK properties or less off-target toxicity; b) existing drugs (candidates) being repurposed to treat CS; and c) novel strategies such as selective inhibition of CYP11B1. Expert opinion: New compounds against established targets need to be developed because current drugs lack selectivity leading to off-target toxicity. Selective inhibition of CYP11B1 is a novel alternative strategy and is potentially versatile in controlling all types of hypercortisolism. Selective multi-targeting enzymes in steroidogenesis network is promising due to potential synergistic effects. However, doses toward each targets are not feasible to adjust because the corresponding intrinsic potencies are rigid. Targeting PRKACA mutations is promising in treating CS caused by adrenal adenomas.
authors.affiliation: a College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China PR.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.affiliation: b Haverhill , UK.
authors.forename: Lina
authors.initials: L
authors.lastname: Yin
authors.affiliation: c Department of Chemistry , University of Cambridge , Cambridge , UK.
authors.forename: Qingzhong
authors.initials: Q
authors.lastname: Hu
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000818:Animals; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D054751:Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / Q000235:genetics; D015195:Drug Design; D006801:Humans; D006854:Hydrocortisone / Q000096:biosynthesis; D009154:Mutation; D010330:Patents as Topic; D015398:Signal Transduction / Q000187:drug effects; D013252:Steroid 11-beta-Hydroxylase / Q000037:antagonists & inhibitors
chemical_list: D000324:Adrenocorticotropic Hormone; D013252:Steroid 11-beta-Hydroxylase; D054751:Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; C517757:PRKACA protein, human; D006854:Hydrocortisone
keywords: CYP11B1 inhibitors; Cortisol; Cushing’s syndrome; hypercortisolism; multi-targeting; patents; pharmaceutical therapies; selectivity